1	Pandemic ST131 Escherichia coli presenting the UPEC/EAEC and ExPEC/EAEC
2	hybrid pathotypes recovered from extraintestinal infections in a clinical setting of the
3	Brazilian Amazon region
4	
5	Nathália M. S. Bighi <sup>1</sup> , Érica L. Fonseca <sup>1,*</sup> , Fernanda S. Freitas <sup>1</sup> , Sérgio M. Morgado <sup>1</sup> and
6	Ana Carolina P. Vicente <sup>1</sup>
7	
8	<sup>1</sup> Laboratório de Genética Molecular de Microrganismos, Instituto Oswaldo Cruz, FIOCRUZ,
9	Rio de Janeiro, Brazil.
10	
11	Correspondence: Érica L. Fonseca, <u>ericafon@ioc.fiocruz.br</u>
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

### Abstract

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Escherichia coli is part of the commensal microbiota of human's and animal's gut. However, they may become pathogenic due to the acquisition of virulence factors that provide the ability to cause intestinal or extraintestinal infections, which makes E. coli the main cause of diarrheagenic diseases and urinary tract infections (UTIs) worldwide, respectively. Some strains, known as hybrids, may harbour a mix of virulence determinants of both diarrheagenic (DEC) and extraintestinal E. coli (ExPEC) pathotypes. Reports of hybrid E. coli in Brazil are rare, and the lineages associated with such pathotypes were poorly explored. This study aimed to characterize E. coli strains recovered from extraintestinal infections in a clinical setting of the Brazilian Amazon Region by means of lineage determination, antibiotic resistance profile, and investigation of DEC and ExPEC virulence markers. Fifteen ExPEC strains were recovered from distinct extraintestinal sites from inpatients of the General Hospital of Roraima (GHR), placed in the Brazilian Amazon region. Antibiotic susceptibility test revealed that all strains were multidrug-resistant and most of them, including those recovered from urine, were resistant to fluoroquinolones, the main therapeutic option for treating UTIs, probably due to the presence of Ser83Leu and Asp87Asn substitutions in GyrA. The MLST analysis revealed the polyclonal nature of these ExPEC strains since 11 STs were determined, including local and pandemic lineages, such as ST69 and ST131. Among the 15 isolates, 12 were classified as hybrids, due to the presence of the aggR virulence marker of the Enteroaggregative E. coli (EAEC) pathotype together with at least one ExPEC (iutA, KPSMTII, sfaDE, papC, afaBC, iucD) or Uropathogenic E. coli (UPEC) (vat, fuyA, chuA and yfcV) virulence determinants. These UPEC/EAEC (n=10) and ExPEC/EAEC (n=2) hybrid strains were found among distinct lineages, including new STs, and phylogroups (ST131/B2; ST1196/AxB1; ST9403/A; ST12394/A; NEW1-CC14/B2; NEW2-CC155/B1; NEW3-CC155/B1; NEW4-CC131/B2) and, for the first time, a hybrid

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

phenotype was found in the pandemic ST131 lineage in Brazil. Therefore, this study provides new information on the epidemiological scenario of hybrid E. coli strains, contributing to a better understanding of the occurrence and pathogenic potential of these organisms. Keywords: HyPEC; ExPEC; ST69; ST131; virulence marker; pandemic lineage **INTRODUCTION** Escherichia coli inhabits the intestinal tract of humans and other animals as an important member of their microbiota [1]. However, the acquisition by horizontal gene transfer of virulence determinants by certain E. coli clones has enabled them to cause not only intestinal but also extraintestinal infections in different hosts. In this way, based on the body site of infection, the host, and the presence of specific virulence markers, these bacteria can be classified into diarrheagenic (DEC), mainly featured by the presence of specific virulence factors directly related to diarrhoea, and extraintestinal pathogenic (ExPEC) E. coli, defined primarily by their site of isolation [2]. The DEC group encompasses several pathotypes, including enterotoxigenic (ETEC), enteropathogenic (EPEC), enteroinvasive (EIEC), enteroaggregative (EAEC), and Shiga toxin-producing (STEC) E. coli. EPEC and EAEC are considered the major pathotypes of diarrheagenic E. coli causing disease worldwide, including in Brazil. These pathotypes carry genetic determinants involved with disease development and can be used as molecular markers of the pathotype. The ExPEC group includes the pathotypes neonatal meningitis-associated (NMEC), human sepsis-associated (SEPEC), avian pathogenic (APEC), and uropathogenic (UPEC) E. coli, which is the most prevalent pathotype among extraintestinal infections worldwide.

UPEC is particularly associated with urinary tract infections (UTIs) and is a leading cause of

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

both community-acquired and healthcare-associated UTIs. Currently, the most frequently reported high-risk ExPEC lineages belonging to the MLST sequence type ST131, ST69, ST10, ST405, ST38, ST95, ST648, ST73 and ST1193, which are known for their high prevalence in extraintestinal infections worldwide and for their significant role in global spread of multidrug resistance [3]. Studies in vivo revealed that the presence of at least two of five virulence genes (pap, afa/dra, sfa, kpsMTII, and iut/iuc) could be enough to cause extraintestinal infection in immunocompetent individuals [4], and that E. coli co-harbouring of chuA, fyuA, vat, and yfcV virulence genes were able to cause UTIs [5]. Additionally, due to horizontal gene transfer events, organisms may emerge as hybrid strains capable of causing intestinal and extraintestinal diseases due to the presence of virulence factors of both ExPEC and DEC pathotypes [6]. Strains harbouring a blend of virulence markers of different pathotypes have been described worldwide in both high-risk and local lineages, however, most of them correspond to hetero-pathogenic strains (characterized by a combination of virulence markers from DEC pathotypes) [7-9]. A recent study in South Africa demonstrated the high prevalence of several different DEC hybrid pathotypes, including strains sharing three virulence markers of three different DEC pathotypes, which were recovered from inanimate surfaces and presented a higher resistance profile compared to the classic pathotypes identified [8]. Another report demonstrated the occurrence of different DEC hybrid strains recovered from healthy individuals in Mexico [9]. In Brazil, few studies have characterized and reported the occurrence of hybrid strains in extraintestinal infection cases harbouring the combination of DEC and ExPEC or

UPEC virulence markers, such as UPEC/EAEC, UPEC/aEPEC, ExPEC/STEC,

ExPEC/aEPEC [10-18]. However, there is a lack of association concerning the STs of such hybrid strains circulating in the country. Moreover, most of these reports on hybrid strains were restricted to São Paulo, a cosmopolitan city of the Southeast Brazilian region, and until now, all studies reporting *E. coli* infections in the Amazon Region were associated only with diarrheagenic infections [19-22]. Therefore, further studies are required to investigate the distribution and potential impact of these strains on the clinical outcomes of affected individuals. For these reasons, the objective of this study was to characterize *E. coli* strains recovered from extraintestinal infections in the Brazilian Amazon Region by means of lineage determination (MLST), antibiotic resistance profile, and investigation of DEC and ExPEC virulence markers.

## **METHODS**

### Clinical data, bacterial strains and antimicrobial susceptibility test

From December 2016 to February, 2018, 15 *E. coli* isolates were recovered from extraintestinal infection cases at the General Hospital of Roraima (GHR), placed in Boa Vista. The strains were isolated from blood (n=2), urine (n=7), catheter tip (n=1), vagina secretion (n=1), leg secretion (n=1), soft tissue (n=1), and operative wound secretion (n=2). Species identification was performed with the automated VITEK2, and confirmed by sequencing the 16S rRNA and the MLST genes. These strains are part of the Bacterial Culture Collection of the Laboratory of Molecular Genetics of Microrganisms, FIOCRUZ.

### **Antimicrobial Susceptibility testing**

The antibiotic susceptibility profile was determined by disc-diffusion method according to clinical and laboratory standards institute (CLSI) guidelines [23] For the following antibiotics: gentamicin, amikacin, kanamycin, tobramycin, neomycin, streptomycin, imipenem, meropenem, ertapenem, cephalothin, cefoxitin, cefuroxime, ceftazidime, ceftriaxone, cefotaxime, cefepime, azithromycin, clarithromycin, erythromycin, ampicillin, ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanic acid, carbenicillin, penicillin, aztreonam, piperacillin/tazobactam, ticarcillin/clavulanic acid, nalidixic acid, ciprofloxacin, norfloxacin, levofloxacin, ofloxacin, colistin sulphate, sulphonamide, trimethoprim, sulfamethoxazole/trimethoprim, chloramphenicol, fosfomycin, nitrofurantoin, tetracycline and minocycline.

### Genotyping by Multilocus sequence typing (MLST)

The genetic relationship among the ExPEC strains was established by MLST based on the Achtman MLST scheme (*adk*, *fumC*, *gyrB*, *icd*, *mdh*, *purA* and *recA*) (http://mlst.warwick.ac.uk). Clonal complexes (CCs) were considered when sequence types (STs) shared five or more identical alleles taking into account the seven genes considered in the MLST scheme.

### Detection of resistance genes by polymerase chain reaction (PCR) and sequencing

The isolates were screened by PCR and sequencing for the presence of the genes frequently associated with  $\beta$ -lactam resistance in  $E.\ coli$  such as  $bla_{SHV},\ bla_{GES},\ bla_{TEM},\ bla_{CTX-M}$  (class A  $\beta$ -lactamases). The plasmid-mediated fluoroquinolone (FQ) resistance qnr genes and the presence of mutations in the quinolone resistance-determining region (QRDR) of gyrA was also investigated (Table 1).

### **Molecular Characterization of Hybrid Strains**

141

142

143

144

145

146

147

148

149

150

151

152153

154

155

156

157

158

159

160

161

162

163

164

165

166

The presence of DEC and ExPEC virulence determinants was screened by PCR (Table 1). Those strains presenting at least one of the DEC pathotypes virulence markers were considered hybrid strains [13]. The DEC virulence factors screened were *eae* and *bfpB* genes, associated with epithelial adhesion in EPEC; the aggR gene, a universal regulator of EAEC virulence involved with the aggregative adhesion fimbriae (AAF) production; the stx1 and stx2 genes, related to the Shiga toxins production in STEC; the estH, estP and elT, involved with the production of heat-stable and heat-labile toxins in ETEC; the *invE* gene that encodes a regulatory protein that controls the transcriptional of invasion genes in EIEC pathotype; the vat, fuyA, chuA and yfcV, all markers of UPEC; and ExPEC markers iutA, KPSMTII, sfaDE, papC, afaBC, iucD. RESULTS AND DISCUSSION The phenotypic analysis revealed that all E. coli ExPEC strains (n=15) were classified as multidrug-resistant (MDR) according to resistance classification criteria [24] (Table 1). Among the  $\beta$ -lactam antibiotics, all isolates were resistant to at least one of these antibiotics, and such phenotype could be explained by the presence of the  $bla_{\text{TEM}}$  gene in 14/15 isolates. In fact, bla<sub>TEM</sub> is frequently associated with plasmids in E. coli, and it was the most prevalent gene among ExPEC recovered from UTI cases in São Paulo, Brazil [25]. However, although the bla<sub>CTX-M</sub> has been frequently associated with ExPEC in Brazil and worldwide [26], this gene was not found in our sample, as well as the other screened  $\beta$ -lactamase genes  $bla_{GES}$  and blashy. Moreover, a high prevalence of fluoroquinolone resistance was observed (73%) among the ExPEC strains. Although none of them carried any qnr allele, all FQ-resistant isolates presented mutations in the Quinolone Resistance-Determining Region (QRDR) of

gyrA that led to the amino acid substitution Ser83Leu and Asp87Asn, known to be involved

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

with FQ resistance emergence [27]. Interestingly, these substitutions were recently reported as the determinants of FQ resistance in ExPEC strains recovered from UTI cases in São Paulo [12]. The MLST analysis revealed a great diversity, in which 11 STs were assigned to the 15 ExPEC strains: ST69, ST131, ST8886, ST1196, ST9403, ST3180, ST12394, and four different new sequence types belonging to CC155 (n=2), CC14 (n=1) and CC131 (n=1), demonstrating the polyclonal nature of these hybrid strains. The most prevalent lineage among our sample was ST131, a pandemic clonal complex of the B2 phylogroup often associated with an arsenal of resistance and virulence genes, contributing to the success of this clone in spreading through clinical settings worldwide. The ST69 is another pandemic lineage belonging to the phylogroup D usually associated with clinics and food/environment contamination in several countries [27]. As found here, Lara and Colleagues have demonstrated the occurrence of ExPEC ST69 presenting the hybrid pathotype UPEC/EAEC in Brazil [10]. However, in spite of ST131 prevalence in Brazil, this is the first report of this lineage presenting a hybrid pathotype (UPEC/EAEC) in that country (Table 2). Considering the *E. coli* virulome, 9/19 virulence factors characterizing DEC and ExPEC pathotypes were found in the studied samples in different frequencies and combinations (Table 2). The presence of at least one extraintestinal virulence marker was observed in all isolates, corroborating the nature of the infection sites from which they were recovered. The *iucD* gene, which is part of the operon involved with aerobactin siderophore synthesis, was the most prevalent ExPEC marker among the isolates (12/15). This gene is associated with iron uptake systems, facilitating its survival and pathogenicity and playing a crucial role in the bacteria's ability to cause infections and evade the host's immune response. Among the 15 ExPEC isolates analysed, 12 (80%) had at least one marker used to define ExPEC and DEC pathotypes, being characterized as hybrid strains. The three strains

classified as non-hybrids belonged to the pandemic lineages ST131/phylogroup B2 (EC44) and ST69/phylogroup D (EC39) and to the local ST8886 (EC40). Only 13 entries in Enterobase (<a href="https://enterobase.warwick.ac.uk/species/index/ecoli">https://enterobase.warwick.ac.uk/species/index/ecoli</a>) have been found for ST8886, and in most cases, they corresponded to strains recovered from environmental sites in USA in 2015 and only one recovered from an animal source in Canada in 2022. Thus, this study reported the first clinical case belonging to this lineage.

Concerning the hybrid strains, it was verified the presence of UPEC/EAEC (n=10) and ExPEC/EAEC (n=2) (when UPEC markers were absent, or the strain had been recovered from a different body site other than urine). The *aggR* gene, considered a diarrheagenic factor that defines the EAEC pathotype, was found in all hybrid isolates, indicating that they would have the ability to cause intestinal disorders despite presenting in extraintestinal infections. EAEC is recognized as an important cause of diarrhoea worldwide and can be considered the most common DEC pathotype in *E. coli* in Brazil. However, *E. coli* strains with a hybrid enteroaggregative/uropathogenic (UPEC/EAEC) genotype have sporadically emerged as a cause of extraintestinal infections in Brazil [10-18]. Here we demonstrated the high prevalence of such hybrid pathotypes in distinct lineages causing infections in the Amazon region.

Most of UPEC/EAEC hybrid strains belonged to the pandemic and widespread ST131 (one of them was assigned to a new ST of the CC131) (Table 2). They were recovered from distinct extraintestinal sites and presented a heterogeneous profile of virulence markers. The unique non-hybrid ST131 strain was the EC44, which was a UPEC recovered from UTI that presented both UPEC and ExPEC virulence markers. On the other hand, local STs (ST9403, ST3180 and ST12394) belonging to different phylogroups (A, B1 and B2) and recovered from distinct body sites, including blood, were also classified as UPEC/EAEC hybrid strains.

Interestingly, in spite of the diversity of infection sites, most of the ExPEC strains were recovered from urine, and all but one were resistant to the tested fluoroquinolones (Table 2), which are the first choice antibiotics for treating UTIs. These findings probably accounted for treatment failure, compromising the success of clinical outcomes.

Interestingly, in spite of the UPEC/EAEC EC49 strain being a new local ST of CC14/phylogroup B2, this isolate exhibited the highest number of ExPEC and UPEC virulence markers, besides the EAEC marker aggR (Table 2). This demonstrates that not only pandemic high-risk clones display an enhanced pathogenicity and that emerging strains may possess a high level of virulence fitness.

The other class of hybrids (ExPEC/EAEC) corresponded to strains (n=2) that carried ExPEC virulence markers and the *aggR* EAEC marker. The strains belonged to a new ST from CC155/phylogroup B1 (EC52) and to the local ST1196 belonging to phylogroup AxB1 (EC47) (Table 2). A recent study in Mozambique demonstrated that a hybrid ExPEC/EAEC strain recovered from blood belonged to the pandemic ST131 lineage and presented a remarkable virulence profile [28]. These findings revealed that ExPEC/EAEC hybrids are associated with distinct lineages. Interestingly, both ExPEC/EAEC strains identified here were recovered from urine although no UPEC virulence marker had been identified. This was also the case of the non-hybrid EC39 strain, belonging to the pandemic ST69/phylogroup D, that had been characterized as a UPEC pathotype due to the site of infection (urine), although all UPEC virulence markers were absent (Table 2). These findings suggest that their ability to infect the urinary tract would be related to other mechanisms that were not investigated in this study. In fact, UPEC employs various virulence strategies, such as binding to urinary tract epithelial cells, iron acquisition, toxin production, and evasion of the host's immune system. These virulence factors are commonly encoded by

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

genes found in pathogenicity islands (PAIs), which are often mobilized through horizontal gene transfer and could have been lost from those UPEC strains [14]. Furthermore, the presence of UPEC factors in strains recovered from sites other than urine, such as the nonhybrid EC40 strain (Table 2), demonstrates their ability to colonize and survive in the urinary tract, but also that other virulence determinants were involved in the establishment of extraintestinal infections in those cases. **CONCLUSION** This study contributes to a better understanding of the occurrence and pathogenic potential of hybrid strains of E. coli. Besides, the association of pathotype and lineage definition provides new information in the scenario of the global epidemiology of ExPEC hybrid strains. **Funding information** This work was supported by Oswaldo Cruz Institute grant, Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Processo SEI-260003/019688/2022. **Conflicts of interest** The authors declare that there are no conflicts of interest. **Ethical statement** This study was approved by the Oswaldo Cruz Foundation Ethics Committee (CAAE: 39978114.5.0000.5248).

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

References 1. **Leimbach A, Hacker J, Dobrindt U.** E. coli as an all-rounder: the thin line between commensalism and pathogenicity. Curr Top Microbiol Immunol 2013;358:3-32. 2. Sora VM, Meroni G, Martino PA, Soggiu A, Bonizzi L, et al. Extraintestinal Pathogenic Escherichia coli: Virulence Factors and Antibiotic Resistance. Pathogens 2021;10:1355. 3. Kocsis B, Gulyás D, Szabó D. Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones of Escherichia coli. *Life (Basel)* 2022; 12:2077. 4. Johnson JR, Murray AC, Gajewski A, Sullivan M, Snippes P, et al. Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products. Antimicrob Agents Chemother 2003;47:2161-2168. 5. Spurbeck RR, Dinh PC Jr, Walk ST, Stapleton AE, Hooton TM, et al. Escherichia coli isolates that carry vat, fyuA, chuA, and yfcV efficiently colonize the urinary tract. Infect Immun 2012;80:4115-4122. 6. Braz S, Melchior K, Moreira CG. Escherichia coli as a Multifaceted Pathogenic and Versatile Bacterium. Front Cell Infect Microbiol 2020;10:1–9. 7. Lee W, Sung S, Ha J, Kim E, An ES, et al. Molecular and Genomic Analysis of the Virulence Factors and Potential Transmission of Hybrid Enteropathogenic and Enterotoxigenic Escherichia coli (EPEC/ETEC) Strains Isolated in South Korea. Int J Mol Sci 2023;24:12729.

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

8. Rakhalaru P, Munzhedzi L, Abia ALK, Kabue JP, Potgieter N, et al. Prevalence and Antimicrobial Resistance Profile of Diarrheagenic Escherichia coli from Fomites in Rural Households in South Africa. Antibiotics (Basel) 2023;12:1345. 9. Méndez-Moreno E, Caporal-Hernandez L, Mendez-Pfeiffer PA, Enciso-Martinez Y, López RR, et al. Characterization of Diarreaghenic Escherichia coli Strains Isolated from Healthy Donors, including a Triple Hybrid Strain. Antibiotics (Basel) 2022;11:833. 10. Lara FBM, Nery DR, Oliveira PM, Araujo ML, Carvalho FRQ, et al. Virulence Markers and Phylogenetic Analysis of Escherichia coli Strains with Hybrid EAEC/UPEC Genotypes Recovered from Sporadic Cases of Extraintestinal Infections. Front Microbiol 2017;8:146. 11. Schüroff PA, Abe CM, Silva JW, Coelho CP, Andrade FB, et al. Role of aggregate-forming pilus (AFP) in adherence and colonization of both intestinal and urinary tracts. Virulence 2022;13:1423-1433. 12. Nascimento JAS, Santos FF, Valiatti TB, Santos-Neto JF, Santos ACM, et al. Frequency and Diversity of Hybrid Escherichia coli Strains Isolated from Urinary Tract Infections. Microorganisms 2021;9:693. 13. Nascimento JAS, Santos FF, Santos-Neto JF, Trovão LO, Valiatti TB, et al. Molecular Epidemiology and Presence of Hybrid Pathogenic Escherichia coli among Isolates from Community-Acquired Urinary Tract Infection. *Microorganisms* 2022; 10:302.

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

14. Tanabe RHS, Dias RCB, Orsi H, de Lira DRP, Vieira MA, et al. Characterization of Uropathogenic Escherichia coli Reveals Hybrid Isolates of Uropathogenic and Diarrheagenic (UPEC/DEC) E. coli. *Microorganisms* 2022;10:645. 15. Furlan JPR, Ramos MS, Dos Santos LDR, Rosa RS, Stehling EG. Multidrugresistant Shiga toxin-producing Escherichia coli and hybrid pathogenic strains of bovine origin. Vet Res Commun 2023; online ahead of print. 16. Munhoz DD, Richards AC, Santos FF, Mulvey MA, Piazza RMF. E. coli Common pili promote the fitness and virulence of a hybrid aEPEC/ExPEC strain within diverse host environments. Gut Microbes 2023;15:2190308. 17. de Lira DRP, Cavalcanti AMF, Pinheiro SRS, Orsi H, Dos Santos LF, et al. Identification of a hybrid atypical enteropathogenic and enteroaggregative Escherichia coli (aEPEC/EAEC) clone of serotype O3:H2 associated with a diarrheal outbreak in Brazil. Braz J Microbiol 2021;52:2075-2079. 18. Valiatti TB, Santos FF, Santos ACM, Nascimento JAS, Silva RM, et al. Genetic and Virulence Characteristics of a Hybrid Atypical Enteropathogenic and Uropathogenic Escherichia coli (aEPEC/UPEC) Strain. Front Cell Infect Microbiol 2020;10:492. 19. Vicente AC, Teixeira LF, Iniguez-Rojas L, Luna MG, Silva L, et al. Outbreaks of cholera-like diarrhoea caused by enterotoxigenic Escherichia coli in the Brazilian Amazon Rainforest. Trans R Soc Trop Med Hyg 2005;99:669-674. 20. Benevides-Matos N, Pieri FA, Penatti M, Orlandi PP. Adherence and virulence genes of Escherichia coli from children diarrhoea in the Brazilian Amazon. Braz J Microbiol 2015;46:131-137.

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

21. Taborda RLM, Silva LAD, Orlandi PP, Batista FS, Rodrigues RS, et al. Characterization of enteroaggregative Escherichia coli among diarrheal children in Western Brazilian Amazon. Arq Gastroenterol 2018;55:390-396. 22. Rodrigues RS, Lima NCDS, Taborda RLM, Esquerdo RP, Gama AR, et al. Antibiotic resistance and biofilm formation in children with Enteropathogenic Escherichia coli (EPEC) in Brazilian Amazon. J Infect Dev Ctries 2019;13:698-705. 23. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing supplement M100. 32nd Ed. Wayne, PA: CLSI; 2021. 24. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–281. 25. Santos-Neto JF, Santos ACM, Nascimento JAS, Trovão LO, Santos FF, et al. Virulence Profile, Antibiotic Resistance, and Phylogenetic Relationships among Escherichia coli Strains Isolated from the Feces and Urine of Hospitalized Patients. Pathogens 2022;11:1528. 26. **Bevan ER, Jones AM, Hawkey PM.** Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother 2017; 72:2145–2155. 27. **Riley LW.** Pandemic lineages of extraintestinal pathogenic Escherichia coli. *Clin* Microbiol Infect 2014;20:380-390. 28. Santona A, Sumbana JJ, Fiamma M, Deligios M, Taviani E, et al. High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from

# Table 1. Primers used in this study

382

Primer name	Primer sequence (5' – 3')	Target
	Antibiotic resistance ge	nes
SHV F	TTCATGGCGTTACCTTTGAC	Class A $\beta$ -lactamase $bla_{SHV}$ genes
SHV R	CCGACAGAGTGCGGTATTTA	
GES F	ATGCGCTTCATTCACGCAC	ESBL Class A $\beta$ -lactamase $bla_{GES}$ genes
GES R	CTATTTGTCCGTGCTCAGGA	
TEM F	GTATCCGCTCATGAGACAATA	Class A $\beta$ -lactamase $bla_{\text{TEM}}$ genes
TEM R	TCTAAAGTATATGAGTAAACTTGGTCTG	,
CTX-M F	CGCTTTGCGATGTGCAG	ESBL Class A β-lactamase <i>bla</i> <sub>CTX-M</sub> genes
CTX-M R	ACCGCGATATCGTTGGT	,
QnrVC F	AAGTGAACTTCTCACATCAGG	Quinolone resistance <i>qnrVC</i> genes
QnrVC R	ATGATTACCCCTAATTGCTCC	1 0
QnrA F	GATTTCTCACGCCAGGATTT	Quinolone resistance <i>qnrA</i> gene
QnrA R	TCKGAGCCCATCAAGGAAG	1 8
QnrB F	GATCGWGAAAGYCAGAAAGG	Quinolone resistance <i>qnrB</i> gene
QnrB R	CCACARYTCRCAYTTTTC	
QnrC F	TGCAGACCTACGAGATGCTT	Quinolone resistance <i>qnrC</i> gene
QnrC R	TTCACGCCAGTTAAATCCAC	Q 4 4 4 8
QnrS F	ACGTGTTAACTTGCGTGAT	Quinolone resistance qnrS gene
QnrS R	GCAATTTTGATACCTGATG	Quinorone resistance qui s gene
GyrA F	CGTTGGTGACGTAATCGGTA	QRDR of gyrA gene
GyrA R	GTGTTCCATCAGCCCTTCA	Question gymigene
<u> </u>	Virulence genes	
Eae F	GTGGCGAATACTGGCGAGACT	
Eae R	CGACGGTGAAAAAGAATGGGG	EPEC virulence marker
BfpB F	CGATAAAACTGATACTGGGCAGC	El Es virgiones marker
BfpB R	GTGCTTCCCGAACAGTCACT	
AggR F	CGATACATTAAGACGCCTAAAG	EAEC virulence marker
AggR R	TCTGATACATTAAATTCATCTGC	
Stx1 F	CAGTTAATGTGGTGGCGAAGG	
Stx1 R	CACCAGACAATGTAACCGCTG	STEC virulence marker
Stx2 F	ATCCTATTCCCGGGAGTTTACG	STEE (Indience market
Stx2 R	GCGTCATCGTATACACAGGAGC	
EstH F	GCTAAACCAGTAGAGTC	
EstH R	CACCCGGTACAAGCAGG	
EstP F	AGTCAGTCAACTGAATCAC	ETEC virulence marker
EstP R	ATTTTCTCAGCACCAATAC	DIDE virulence marker
elT F	CACACGGAGCTCCTCAG	
elT R	CAAACTAGTTTTCCATACTG	
invE F	CGATAGATGGCGAGAAATTATATCCCG	EIEC virulence marker
invE I	CGATCAAGAATCCCTAACAGAAGAATCA	LILE VITUICIEC Market
Vat F	TCAGGACACGTTCAGGCATTCAGT	
Vat R	GGCCAGAACATTTGCTCCCTTGTT	
	GTAAACAATCTTCCCGCTCGGCAT	
FyuA F	TGACGATTAACGAACCGGAAGGGA	UPEC virulence marker
FyuA R ChuA F	CTGAAACCATGACCGTTACG	OF EC VITUIENCE MAIKEI
ChuA R	TTGTAGTAACGCACTTCACC	
yfcV F	ACATGGAGACCACGTTCACC	

yfcV R iutA F iutA R KpsMTII F KpsMTII R sfaDE F sfaDE R papC F papC R afaBC F afaBC R iucD F iucD R 383	GTAATCTGGAATGTGGTCAGG GGCTGGACATCATGGGAACTGG CGTCGGGAACGGGTAGAATCG GCGCATTTGCTGATACTGTTG CATCCAGACGATAAGCATGAGCA CTCCGGAGAACTGGGTGCATCTTAC CGGAGGAGTAATTACAAACCTGGCA GTGGCAGTATGAGTAATGACCGTTA ATATCCTTTCTGCAGGGATGCAATA GGCAGAGGGCCGGCAACAGGC CCCGTAACGCGCCAGCATCTC TCCTCATTTTTCCTGGCATC AGTTTATTTCCGCCGCTTCT	ExPEC virulence marker	
384			
385			
386			
387			
388			
389			
390			
391			
392			
393			
394			
395			
396			
397			
398			
399			
400			
401			

medRxiv preprint doi: https://doi.org/10.1101/2024.03.11.24304096; this version posted March 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license.

Γable 2. Clinical and genetic information of the hybrid *E. coli* strains in this study

Strain	Infection site	ST	CC	Phylogroup	Antibiotic resistance profile	Pathotype Genetic Markers			Hybrid ## ## ## ## ## ## ## ## ## ## ## ## ##
	site								Classification a < a ii a b ie
						DEC	EXPEC	UPEC	able u
EC39	Urine	69	69	D	NEO, CEF, CLA, ERI, CB, AMP, PEN, SXT, SUL,	-	kpsMTII	-	under a O
					TMP				C-BY-I
EC40	Blood	8886	-	B2	NEO, CXM, AZI, CLA, ERI, AMP, PEN, SXT, SUL, TMP	-	-	fyuA, yfcV	a CC-BY-ND 4.0 Internationa
					KAN, NEO, STR, CEF, FOX, CXM, CAZ, CRO,				nation
EC41	Leg	131	131	B2	CTX, FEP, AMP, AMX, CB, PEN, TIM, CLA, ERI,	aggR	iucD	fyuA, yfcV	UPEC/EAEC license
	secretion				NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP, MIN				nse.
EC42	Urine	131	131	B2	GEN, TOB, KAN, NEO, STR, CEF, FOX, CXM, CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC,	aggR	iucD	yfcV	UPEC/EAEC .
					CB, PEN, TIM, ATM, CLA, ERI, NAL, CIP, NOR,				

# medRxiv preprint doi: https://doi.org/10.1101/2024.03.11.24304096; this version posted March 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

# LEV, OFX, SXT, SUL, TMP, MIN, TET

					NEO, STR, CEF, FOX, CXM, CAZ, CRO, CTX,				
EC43	Catheter tip	131	131	B2	FEP, AMP, AMX, CB, PEN, TIM, AZI, CLA, ERI,	aggR	iutA, kpsMTII, iucD	yfcV	UPEC/EAEC
					NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP, TET				
EC46	Soft tissue	NEW 4	131	B2	GEN, TOB, KAN, NEO, CEF, FOX, CXM, CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB,	aggR	iutA, kpsMTII, papC, iucD	fyuA, yfcV	UPEC/EAEC
					PEN, TIM, ATM, CLA, NAL, CIP, NOR, LEV, OFX				
EC47	Urine	1196	-	AxB1	KAN, NEO, CEF, AMP, CB, PEN, AZI, CLA, ERI,	aggR	iutA, afaBC	-	EXPEC/EAEC
					NAL, CIP, NOR, LEV, OFX				-
EC48	Vagina	9403	-	A	KAN, NEO, STR, AMP, CB, PEN, AZI	aggR	iutA, kpsMTII,	fyuA, yfcV	UPEC/EAEC
	secretion						papC, iucD		
					GEN, TOB, KAN, NEO, STR, CEF, FOX, CXM,				
EC44	Urine	131	131	B2	CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC,	-	iutA, kpsMTII,	fyuA, yfcV	-
					CB, PEN, TIM, ATM, AZI, CLA, ERI, NAL, CIP,		papC iucD		
					NOR, LEV, OFX, SXT, SUL, TMP, TET				

TOB, KAN, NEO, STR, CEF, FOX, CXM, CAZ,

EC45	Urine	131	131	B2	CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB,	aggR	iutA, kpsMTII,	fyuA, yfcV	UPEC/EAEC
					PEN, TIM, TZP, ATM, AZI, CLA, ERI, NAL, CIP,		afaBC, iucD		
					NOR, LEV, OFX, SXT, SUL, TMP				
					KAN, NEO, STR, CEF, CTX, AMP, SAM, AMX,		iutA, kpsMTII,	vat, fyuA,	
EC49	Urine	NEW 1	14	B2	AMC, CB, PEN, TIM, AZI, CLA, ERI, NAL, CIP,	aggR	papC, afaBC, iucD	yfcV	UPEC/EAEC  UPEC/EAEC  UPEC/EAEC  UPEC/EAEC  UPEC/EAEC  UPEC/EAEC
					NOR, LEV, OFX, SXT, SUL, TMP				nade a
									waik
EC50	-	3180	14	B2	KAN, NEO, STR, CRO, AMP, PEN, AZI, CLA,	aggR	iutA, kpsMTII, iucD	yfcV	UPEC/EAEC
					ERI, NAL, CIP, NOR, LEV, OFX, CHL				under
									a 2
					KAN, NEO, STR, CEF, CRO, AMP, SAM, AMX,				AB.C
EC51	Blood	NEW 2	155	B1	CB, PEN, TIM, CLA, ERI, SXT, SUL, TMP, MIN,	aggR	iutA, iucD	fyuA	UPEC/EAEC 5
					TET				:0 In:
									<u>o</u>
EC52	Urine	NEW 3	155	B1	AMP, PEN, CLA, NAL, CIP, NOR, LEV, OFX, MIN	aggR	iutA, afaBC, iucD	-	EXPEC/EAEC Expectation is a second control of the second control o
									licen
					AMK, GEN, TOB, KAN, NEO, STR, CEF, FOX,				<u>se</u>
EC53	wound	12394	46	A	CXM, CAZ, CRO, CTX, FEP, AMP, SAM, AMX,	aggR	iutA, iucD	fyuA	UPEC/EAEC
	secretion				CB, PEN, TIM, ATM, AZI, CLA, ERI, NAL, CIP,				EXPEC/EAEC itional license.  UPEC/EAEC
					NOR, LEV, OFX, TMP, MIN, TET				

Abbreviations: AMK, amikacin; GEN, gentamicin; TOB, tobramycin; KAN, kanamycin; NEO, neomycin; STR, streptomycin; CEF, cephalothin; FOX, cefoxitin; CXM, cefuroxime; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; AMP, ampicillin; SAM, ampicillin/sulbactam; AMX, amoxicillin; AMC, amoxicillin/clavulanate; CB, carbenicillin; PEN, penicillin; TIM, ticarcillin/clavulanate; TZP, piperacillin/tazobactam; ATM, aztreonam; AZI, azithromycin; CLA, clarithromycin; ERI, erythromycin; NAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; LEV, levofloxacin; OFX, ofloxacin; SXT, trimethoprim/sulfamethoxazole; SUL, sulphonamide; TMP, trimethoprim; MIN, minocycline; tetracycline; CHL, chloramphenicol.

ExPEC strains presenting hybrid pathotypes in the Amazon region UPEC/EAEC and ExPEC/EAEC (new STs. local STs and pandemic ST131) Amazon region